U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2004). J&J Warned on Claims About Antipsychotic Drug. Psych Central. Retrieved on December 21, 2014, from http://psychcentral.com/blog/archives/2004/04/27/jj-warned-on-claims-about-antipsychotic-drug/

 

Recent Comments
  • Timmy: Sometimes I hate the noise other people make so much I stay in the house with white noise going to block it...
  • carol: Hi Jessymum, can u tell me more about your dietary changes helping to reduce your pain and inflammation? I...
  • jassyly: If anything means, I congrats to you, for being brave. I was growing in severely disfunctuonal...
  • Pamela Jarrett: It took me 8 years to get my hypothyroidism diagnosed. It was ruining my life. I was referred to a...
  • jassyly: Decide to love yourself and honour your life and do please, leave him for good and save your soul. I myself...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code



Users Online: 14398
Join Us Now!